Alnylam Pharmaceuticals, Inc. (ALNY)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Alnylam Pharmaceuticals, Inc. (ALNY)
Company Performance

Current Price

as of Dec 03, 2024

$251.84

P/E Ratio

N/A

Market Cap

$32.48B

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Metrics

Overview

  • HQCambridge, MA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerALNY
  • Price$251.84-0.46%

Trading Information

  • Market cap$32.48B
  • Float99.19%
  • Average Daily Volume (1m)856,718
  • Average Daily Volume (3m)777,009
  • EPS-$2.62

Company

  • Revenue$2.09B
  • Rev growth (1yr)-33.26%
  • Net income-$111.57M
  • Gross margin82.85%
  • EBITDA margin-12.56%
  • EBITDA-$62.92M
  • EV$35.31B
  • EV/Revenue16.86
  • P/EN/A
  • P/S15.46
  • P/B1,002.87
Documents
SEC Filings
8-K (2024-10-31)
8-K (2024-08-01)
8-K (2024-05-20)
8-K (2024-05-02)
8-K (2024-03-04)
8-K (2024-02-15)
8-K (2024-01-19)
8-K (2024-01-08)
8-K (2023-11-02)
8-K (2023-10-10)
8-K (2023-09-28)
8-K (2023-08-03)
8-K (2023-07-26)
8-K (2023-06-30)
8-K (2023-05-23)
8-K (2023-05-04)
8-K (2023-03-08)
8-K (2023-02-23)
8-K (2023-01-09)
8-K (2023-01-06)
10-Q (2024-10-31)
10-Q (2024-08-01)
10-Q (2024-05-02)
10-Q (2023-11-02)
10-Q (2023-08-03)
10-Q (2023-05-04)
10-K (2024-02-15)
10-K (2023-02-23)
Factset Street Account
StreetAccount Metrics Recap - Alnylam Pharmaceuticals Q3 Earnings ($157.00, 0.00) (2023-11-02T12:12:06Z)
StreetAccount Earnings Call Q&A Summary: Alnylam Pharmaceuticals Q3 ($ 150.00, -7.00) (2023-11-02T14:16:52Z)
Follow-up: Alnylam announces Complete Response Letter from FDA for sNDA for Patisiran; call today at 8:30ET ($176.92, 0.00) (2023-10-09T11:34:33Z)
Alnylam Pharmaceuticals reports Q3 GAAP EPS $1.15 vs ($3.32) ($157.00, 0.00) (2023-11-02T12:09:01Z)
Alnylam Pharmaceuticals reports additional positive interim Phase 1 results for ALN-APP, in development for Alzheimer's Disease and Cerebral Amyloid Angiopathy ($160.66, -3.30) (2023-10-25T15:09:12Z)
Alnylam Pharmaceuticals presents results from KARDIA-1 Phase 2 study of zilebesiran at AHA Scientific Sessions (2023-11-11T22:44:11Z)
Alnylam Pharmaceuticals halted, news pending ($176.92, 0.00) (2023-10-09T11:25:54Z)
Alnylam Pharmaceuticals announces publication of APOLLO-B phase 3 study results ($159.49, 0.00) (2023-10-25T21:25:29Z)
Wikipedia
Alnylam_Pharmaceuticals,_Inc.
Earnings Calls
Earnings Report 2024Q3
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-11-02)
Earnings Report (2023-08-03)
Factset
Factset Business Description